NCT04138836已完成1 期
A 3-Part, Phase 1 Study to Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- AUC (the area under the curve) [Pharmacokinetics]
研究概览
简要总结
Study to determine the effect of multiple-dose BBT-877 on the single-dose pharmacokinetics of midazolam, the safety and tolerability of a single dose of BBT-877 administered alone and with multiple doses of itraconazole, and the effect of multiple-dose esomeprazole on the single-dose pharmacokinetics of BBT-877, in healthy adult subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult male and/or female (non-childbearing potential only), 19 to 55 years of age, inclusive, at screening.
- •Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dose and throughout the study.
- •BMI ≥ 18.5 and ≤ 32.0 kg/m2 and weight ≥ 50 kg at screening.
- •Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, as deemed by the PI or designee.
- •No clinically significant history or presence of ECG findings as judged by the PI or qualified designee at screening and first check-in.
- •For a female, must be of non-childbearing potential.
- •A non-vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study drug.
- •If male, must agree to not donate sperm from the first dose until 90 days after the last dose of study drug(s).
- •Must have the ability to understand and sign a written informed consent form (ICF), which must be obtained prior to initiation of study procedures, and be willing and able to comply with the protocol requirements as outlined in the ICF.
排除标准
- •Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
- •History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
- •History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
- •History or presence of alcoholism or drug abuse within the past 2 years prior to the first dose or regular alcohol consumption within 6 months prior to the first dose.
- •History or presence of hypersensitivity or idiosyncratic reaction to the study drug(s) or related compounds.
- •History of anemia or history of decreased red blood cells (RBC).
- •Estimated creatinine clearance <80 mL/min at screening.
- •Liver function tests (serum ALT, AST, alkaline phosphatase) and serum bilirubin (total and direct) > upper limit of normal at screening or first check-in.
- •Baseline hemoglobin, hematocrit, RBC < lower limit of normal at screening and Day -1 of Period
- •Female subjects who are of childbearing potential.
- •Female subjects who are pregnant or lactating.
- •Positive urine drug or alcohol results at screening or first check-in.
- •Positive urine cotinine at screening.
- •Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV).
研究组 & 干预措施
Itraconazole
Experimental
干预措施: BBT-877 (Drug)
Midazolam
Experimental
干预措施: BBT-877 (Drug)
Midazolam
Experimental
干预措施: Midazolam (Drug)
Itraconazole
Experimental
干预措施: Itraconazole (Drug)
Esomeprazole
Experimental
干预措施: BBT-877 (Drug)
Esomeprazole
Experimental
干预措施: Esomeprazole (Drug)
结局指标
主要结局
AUC (the area under the curve) [Pharmacokinetics]
时间窗: Day 1 of period 1 and Day 10 (Arm 1), 5 (Arm 2), or 5 (Arm 3) of period 2
AUC for midazolam and 1-OH-midazolam with and without BBT-877 (Arm 1), and for BBT-877 with and without itraconazole (Arm 2) or esomeprazole (Arm 3)
Cmax (peak concentration) [Pharmacokinetics]
时间窗: Day 1 of period 1 and Day 10 (Arm 1), 5 (Arm 2), or 5 (Arm 3) of period 2
Cmax for midazolam and 1-OH-midazolam with and without BBT-877 (Arm 1), and for BBT-877 with and without itraconazole (Arm 2) or esomeprazole (Arm 3)
次要结局
- Plasma LPA (Lysophosphatidic acid) concentration [Pharmacodynamics (Arm 2 and 3)](Day 1 of period 1 and Day 10 (Arm 1), 5 (Arm 2), or 5 (Arm 3) of period 2)
- Incidence of adverse events [Safety and tolerability](Up to 14 days after the last study drug administration)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and DigoxinHealthyNCT02783040Boehringer Ingelheim13
已完成
1 期
A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart FailureHeart FailureNCT01944683Acorda Therapeutics22
撤回
1 期
Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and DigoxinHealthyNCT02345304Boehringer Ingelheim
已完成
1 期
A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study ParticipantsHealthy Study ParticipantsNCT06679413UCB BIOSCIENCES, Inc.22
已完成
1 期
A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant PatientsHematopoetic Stem Cell TransplantNCT01926899Indiana University15